08:00 , Feb 13, 2012 |  BioCentury  |  Emerging Company Profile

Abide: Selecting serine hydrolases

Abide Therapeutics Inc. is developing an approach to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. Most of the new targets will require significant...
07:00 , May 5, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Arylacetamide deacetylase-like 1 (AADACL1; KIAA1363) An in vitro and mouse study identified an inhibitor of KIAA1363 that may help...
07:00 , Aug 5, 2002 |  BC Week In Review  |  Company News

ActivX other research news

Researchers published in the Proceedings of the National Academy of Sciences the use of proteomics to identify enzymes that are differentially regulated in tumor cells. The screen identified a cluster of proteases, lipases, and esterases...